MedTrace Logo

Dose-Escalation Study in Advanced Colon Cancer Patients

NCT00969046 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-08

No results posted yet for this study

Summary

This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.

Conditions

Interventions

DRUG

EPO906 (patupilone)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Royal London Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • Czechia
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969046 on ClinicalTrials.gov